CEO forced into U-turn over Aids drug price

A US company that raised the price of a drug for treating a deadly parasitic infection by more than 5,000% says it will roll back some of the increase.

Turing Pharmaceuticals CEO Martin Shkreli said the new price would make Daraprim more accessible.

“We’ve agreed to lower the price of Daraprim to a point that is more affordable and is able to allow the company to make a a very small profit,” Mr Shkreli said.